Argenx Se (ARGX) EBIT Growth (1y) (2017 - 2026)
Powered by 
Analysis
Argenx Se (ARGX) EBIT Growth (1y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 8.32% |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 19.82% |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 145.20% |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | 10.14% |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 269.85% |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 1,528.74% |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | -36.55% |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 99.51% |
| 10 | Incyte | 25.59 Bn | 21.05 Bn | 1.57 Bn | 31.60% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 145.20% |
| Mar 31, 2026 | 183.45% |
| Dec 31, 2025 | 256.76% |
| Sep 30, 2025 | 2,340.22% |
| Jun 30, 2025 | 542.27% |
| Mar 31, 2025 | 248.79% |
| Dec 31, 2024 | 174.33% |
| Sep 30, 2024 | 117.60% |
| Jun 30, 2024 | 55.47% |
| Mar 31, 2024 | 9.95% |
| Dec 31, 2023 | -21.14% |
| Sep 30, 2023 | 61.37% |
| Jun 30, 2023 | -219.85% |
| Mar 31, 2023 | 53.42% |
| Dec 31, 2022 | 50.44% |
| Sep 30, 2022 | -3,036.48% |
| Jun 30, 2022 | -73.39% |
| Mar 31, 2022 | -1,713,176.92% |
| Dec 31, 2021 | -126.87% |
| Sep 30, 2021 | 105.99% |